Comparative proteomics of rat brain in the BCNU-induced model of cortical dysplasia / 中华急诊医学杂志

Objective To screen the differential proteins in the brain (neocortex and hippocampus) between the rats with cortical dysplasia (CD) and control ones,and investigate the role of their alteration in the development of epilepsy in CD.Methods Cortical dysplasia was induced in rat pups via in utero delivery of BCNU.A two-dimensional electrophoresis (2-DE)-based approach was used to construct the expression profiles of proteins in both the neocortex and hippocampus at different age groups (postnatal day 7 and 60) and to detect proteome changes between CD rats and control ones.Following gel image analysis,protein spots that differed in abundance between CD and control rats were identified by using Matrx-assisted laser desorption/ionization (MALDI) mass spectrometry (MS) and MS/MS.Results A total of 57 kinds of protein were screened out (P ＜ 0.05),in which 35 were found up-regulated and 22 were down-regulated compared with the control,35 from neonatal stage (postnatal day 7) and others from adult stage.Finally,12 among them were identified,including tubulin,alpha-lB,Beta-actin,tubulin beta-2A,GAP-43,UbCKmit,GAPDH and TMBr-3,etc.Conclusions Changed expression of specific proteins which were found in our study are involved in construction of brain 's cytoskeleton,synaptic function,mitochondrial function and so forth.Thus,they may be related to the pathogenic mechanisms of epileptogenicity of CD.

Pharmacokinetics of BCNU-PLA Delayed Release Wafer Embedded in Brain of Dogs / 中国康复理论与实践

@#Objective To observe the pharmacokinetics and concentration of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in brain tissue after BCNU-polylactic acid (PLA) delayed release wafer embedded in brain tissues of dogs.Methods 10% BCNU-PLA delayed release wafer were prepared and embedded in brains of 12 dogs. Peripheral blood of dogs was taken and the animals were executed for brain tissue after surgery in different times. BCNU concentrations in blood and brain tissue were quantified by high-performance liquid chromatography.Results BCNU was able to be detected at 22nd hour, and the Cmax (average 243.64 ng/ml) appears at 35th hour after surgery. The average BCNU concentration in brain tissue was 26.60 μg/g at 5th day after surgery.Conclusion BCNU-PLA delayed release wafer is a useful type for treatment of malignant gliocoma.

Treatment of the Early Mycosis Fungoides / 대한피부과학회지

BACKGROUND: Mycosis fungoides (MF) is the most frequent form of cutaneous lymphoma. Early stage MF is known to be responsible to the various topical and systemic therapies. However, there have been few clinical reviews of the treatment modalities of the early stoge MF in Korea. OBJECTIVE: The aim of this study is to investigate the therapeutic response of early MF to different treatment modalities. METHODS: The medical records, clinical photographs, and biopsied tissues, of fifty three cases of early MF were reviewed. RESULTS: The mean age at diagnosis of early MF was 43.0 years old (varied between 9 and 81 years old). Twenty three (43.4%) were male and thirty (56.6%) were female. Topical carmustine (bis-chloroethyl-nitrosourea, BCNU) was the most commonly used treatment modality in the early MF (34.0%). Patients treated by BCNU in stage IA ( or =10% skin involved). Even Psoralen plus UVA (PUVA) therapy, which was most efficient in stage IB, revealed a high relapse rate after one year. CONCLUSION: BCNU has been most commonly used for the treatment of early MF during the past 10 years in the authors' hospital. It showed a comparatively high response rate, and the relapse rate of BCNU was lower than for other therapies in stage IA. However many treatments became ineffective when MF progressed to stage IB. Therefore the authors confirm that early diagnosis and proper therapy are most important for the treatment of early MF.

BL for the treatment of brain metastasis lung cancer / 中国医师进修杂志

0.05). WHO grade Ⅲ/Ⅳ neutropenia 10%in BL groups,47% in BCNU groups.The BL groups was longer than BCNU groups in survival time(P

Pulmonary Toxicity Following High-Dose Chemotherapy With Peripheral Blood Stem Cell Transplantation / 결핵

BACKGROUND: High-dose chemotherapy is increasingly employed in many refractory malignant diseases. This therapy has been reported to increase response rate and survival benefits but it is also associated with higher treatment-related morbidity and mortality. We evaluated clinical characteristics and course of the pulmonary toxicity following high-dose chemotherapy with peripheral blood stem cell transplantation. METHODS: Ninety-seven patients who had received high-dose chemotherapy with peripheral blood stem cell transplantation were evaluated. Five patients who developed lung lesions which were not related to infection nor primary malignant disease underwent transbronchial lung biopsy. The patients' clinical characteristics, treatments, and prognosis were reviewed retrospectively. RESULTS: Five patients(5.1%) developed idiopathic pneumonia syndrome. The high dose chemotherapy regimens employed were cyclophosphamide, BCNU, and cisplatin in 3 cases, one case of BCNU, etoposide, Ara-C, cyclophosphamide combination, and a regimen consisting of BCNU, etoposide, Ara-C, and melphalan. The total dose of BCNU used was 300-400 mg/m2 and that of cyclophosphsmide was 6,000 mg/m2. All of 5 patients received radiation therapy before this treatment. After an average duration of 14 weeks (4-26 weeks) of high-dose chemotherapy, patients developed cough, dyspnea and fever. The chest X-rays showed bilateral diffuse infiltration in 3 cases and the focal infiltration in the other 2 cases. All the patients received corticosteroid therapy as a treatment for the lung lesions. Two of them progressed to acute respiratory distress syndrome and died. Three patients recovered without residual lung lesion but one of them died of dilated cardiomyopathy. CONCLUSION: High-dose chemotherapy with peripheral blood stem cell transplantation especially which containing BCNU regimen may develop idiopathic pneumonia syndrome related to pulmonary toxicity and corticosteroid therapy may be beneficial in some cases.

BCNU-CDDP Continuous Infusion Chemotherapy in Recurrent Oligodendroglioma

Eight patients with recurrent oligodendroglioma were treated with 1.3-bis(2-chloroethyl) nitrosourea(BCNU) and CDD continuous infusion chemotherapy. They were 5 with benign oligodendrogliomas and 3 with anaplastic oligodendrogliomas. All the recurrent tumors had been treated with surgery and radiotherapy. Four patients had already received chemotherapy with ACNU. Seven of them showed response to continuous infusion chemotherapy. The time from the response to progression was 15 to 67 weeks. No severe complication of the chemotherapy was found. In conclusion, BCNU-CDDP continuous infusion chemotherapy is an effective treatment modality in recurrent oligodendrogliomas.

An Analysis of Combined interferon-beta, BCNU and Radiation in the Treatment of Malignant Glioma

Prognosis for patients with a malignant glioma of the brain is, up to the present time, very poor. Surgery is unlikely to be curative and the primary goals of the surgery are:(1) to make a histologic diagnosis, (2) to determine the extent of the lesion and (3) if possible, to debulk the tumor. The inclusion of radiation therapy following surgery prolonged median survival time by about 0 weeks as compared to surgery alone or surgery with chemotherapy. 50 patients with anaplastic astrocytoma or glioblastoma multiforme were treated at the Department of Neurosurgery. C.U.M.C. Mar. 1991 and Jul. 1994. All patients were treated with surgical resection, irradiation, chemotherapy with BCNU(1, 3bis(2chloroentlyl) 1nitrosourea), and immunotherapy with interferon beta(IBR therapy). Interferon beta was given in dosages of 100,000~300,000 U for 7 days and BCNU was given in doses of 200mg/sqm for 1 day, intravenously before postoperative radiotherapy and was repeated at the interval of 6 weeks. Survival rates were analyzed between our IBR therapy group and historical data of radiation therapy alone. Several prognostic factors were analyzed in the IBR therapy group. Survival curves were observed according to the Kaplan Meier method. Our observation revealed that IBR therapy showed encouraging results in some patients without stastistical significant in general. However, despite the above observtion, we believe that the statistical out come of the IBR group may change statistically if given a longer follow up period. Furthrmore, our study also demonstrated that the improved survival time gained from total resection over subtotal resection was statistically significant.

Intravenous vs Selective Intraarterial ACNU Chemotherapy on Malignant Gliomas

In 17 cases of glioblastoma multiforme and 3 cases of anaplastic astrocytoma, ACNU chemotherapy was performed by intravenous(10 cases) and supraophthalmic or superselective intraarterial(10 cases) injection postoperatively combined with radiation therapy. The postoperative median survival time in 17 cases of glioblastoma multiforme was 15 months(7 cases alive), and those for intravenous(8 cases) and intraarterial(9 cases) were 16.3 months(2 case alive) and 13 months(5 cases alive) respectively. 3 cases of anaplastic astrocytoma(2 cases intravenous, 1 case intraarterial) are all alive and the average postoperative follow-up period was 22.5 months. The survival rate of patients with gliobalstoma multiforme at 18 months after operation was 47.6%, and those for intravenous and intraarterial were 57.6% and 36.5%. In an analysis of performance status at the time of 3 months following surgery, there was remarkable improvement of quality of life in 70% of glioblastoma multiforme treated. In postoperative 12 months, about 50% of gliobalstoma multiforme patients could carry their normal daily life. Systemic side effects such as leukopenia and thrombocytopenia occurred little more frequently in intravenous group than intraarterial group. But more serious local neurological complication such as visual loss(1 case) and leucoencephalopathy(1 case) occurred in intraarterial group. Platelet count were decreased maximally in the fourth week after ACUN administration.